BridgeBio Pharma, Inc. Common Stock

BBIONASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
79.37 USD
↘ 1.03 (1.28%)AT CLOSE (11:59 AM EDT)
80.78
↗ 1.41 (1.77%)
POST MARKET (AS OF 06:29 PM EDT)
Post Market
AS OF 06:29 PM EDT
80.78
↗ 1.41 (1.77%)
🟢Market: OPEN

BridgeBio Pharma, Inc. Common Stock (BBIO) trades at $80.78 per share. The technical outlook is "Neutral" and the fundamental picture shows "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (27.5%) and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Aug 26, 2026.

Open?$79.75
High?$80.76
Low?$79.33
Prev. Close?$80.40
Volume?1.7M
Avg. Volume?2.1M
VWAP?$79.87
Rel. Volume?0.80x
Bid / Ask
Bid?$75.05 × 100
Ask?$83.40 × 100
Spread?$8.35
Midpoint?$79.23
Valuation & Ratios
Market Cap?15.7B
Shares Out?195.5M
Float?149.1M
Float %?76.2%
P/E Ratio?N/A
P/B Ratio?-6.25
EPS?-$3.54
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
839
Market Cap
15.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.bridgebio.com
Listed
2019-06-27
Address
3160 PORTER DR.
PALO ALTO, CA 94304
Phone: (650) 391-9740
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
90
Short Sent.?
19
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.79Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?15.64%High
Short Interest?23.3M
Days to Cover?10.8
Free Float149.1M
Avg Daily Volume2.2M
Settlement Date2026-08-14
Financial Health
Current Ratio?1.23Adequate
Quick Ratio?1.17Adequate
Cash Ratio?0.76Adequate
Debt/Equity?-0.98Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-6.25CHEAP▾
P/S?
Peers
100
S&P
3
22.04HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-37.1CHEAP▾
EV/Sales?
Peers
100
S&P
3
24.56HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
77
27.5%STRONG▾
ROA?
S&P
3
-56.8%WEAK▾
Cash Flow & Enterprise
FCF?$-435389000
Enterprise Value?$17.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist